Biogen Idec to Present New Data on Diverse Neurological Portfolio at 65th AAN ... MarketWatch (press release) ... (prolonged-release fampridine tablets). The company will also present results from the investigational trials of its late-stage MS pipeline, including TECFIDERA(TM) (dimethyl fumarate), peginterferon beta-1a and daclizumab high-yield process (DAC HYP). |
